Literature DB >> 33427196

Development of antibody-dependent cell cytotoxicity function in HIV-1 antibodies.

Laura E Doepker1, Sonja Danon1, Elias Harkins2, Duncan K Ralph2, Zak Yaffe1,3, Meghan E Garrett1,4, Amrit Dhar2,5, Cassia Wagner3, Megan M Stumpf1, Dana Arenz1, James A Williams6, Walter Jaoko7, Kishor Mandaliya8, Kelly K Lee6, Frederick A Matsen2, Julie M Overbaugh1,2.   

Abstract

A prerequisite for the design of an HIV vaccine that elicits protective antibodies is understanding the developmental pathways that result in desirable antibody features. The development of antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) is particularly relevant because such antibodies have been associated with HIV protection in humans. We reconstructed the developmental pathways of six human HIV-specific ADCC antibodies using longitudinal antibody sequencing data. Most of the inferred naive antibodies did not mediate detectable ADCC. Gain of antigen binding and ADCC function typically required mutations in complementarity determining regions of one or both chains. Enhancement of ADCC potency often required additional mutations in framework regions. Antigen binding affinity and ADCC activity were correlated, but affinity alone was not sufficient to predict ADCC potency. Thus, elicitation of broadly active ADCC antibodies may require mutations that enable high-affinity antigen recognition along with mutations that optimize factors contributing to functional ADCC activity.
© 2021, Doepker et al.

Entities:  

Keywords:  ADCC; HIV; SHM; antibody development; human; immunology; infectious disease; inflammation; microbiology

Mesh:

Substances:

Year:  2021        PMID: 33427196      PMCID: PMC7884072          DOI: 10.7554/eLife.63444

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  58 in total

1.  Antibody framework residues affecting the conformation of the hypervariable loops.

Authors:  J Foote; G Winter
Journal:  J Mol Biol       Date:  1992-03-20       Impact factor: 5.469

Review 2.  Signaling by Antibodies: Recent Progress.

Authors:  Stylianos Bournazos; Taia T Wang; Rony Dahan; Jad Maamary; Jeffrey V Ravetch
Journal:  Annu Rev Immunol       Date:  2017-04-26       Impact factor: 28.527

3.  Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection.

Authors:  Priyamvada Acharya; William D Tolbert; Neelakshi Gohain; Xueji Wu; Lei Yu; Tongyun Liu; Wensheng Huang; Chih-Chin Huang; Young Do Kwon; Robert K Louder; Timothy S Luongo; Jason S McLellan; Marie Pancera; Yongping Yang; Baoshan Zhang; Robin Flinko; James S Foulke; Mohammad M Sajadi; Roberta Kamin-Lewis; James E Robinson; Loïc Martin; Peter D Kwong; Yongjun Guan; Anthony L DeVico; George K Lewis; Marzena Pazgier
Journal:  J Virol       Date:  2014-08-27       Impact factor: 5.103

4.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Chaim A Schramm; Jason Gorman; Penny L Moore; Jinal N Bhiman; Brandon J DeKosky; Michael J Ernandes; Ivelin S Georgiev; Helen J Kim; Marie Pancera; Ryan P Staupe; Han R Altae-Tran; Robert T Bailer; Ema T Crooks; Albert Cupo; Aliaksandr Druz; Nigel J Garrett; Kam H Hoi; Rui Kong; Mark K Louder; Nancy S Longo; Krisha McKee; Molati Nonyane; Sijy O'Dell; Ryan S Roark; Rebecca S Rudicell; Stephen D Schmidt; Daniel J Sheward; Cinque Soto; Constantinos Kurt Wibmer; Yongping Yang; Zhenhai Zhang; James C Mullikin; James M Binley; Rogier W Sanders; Ian A Wilson; John P Moore; Andrew B Ward; George Georgiou; Carolyn Williamson; Salim S Abdool Karim; Lynn Morris; Peter D Kwong; Lawrence Shapiro; John R Mascola
Journal:  Nature       Date:  2014-03-02       Impact factor: 49.962

5.  Antigen-Induced Allosteric Changes in a Human IgG1 Fc Increase Low-Affinity Fcγ Receptor Binding.

Authors:  Chiara Orlandi; Daniel Deredge; Krishanu Ray; Neelakshi Gohain; William Tolbert; Anthony L DeVico; Patrick Wintrode; Marzena Pazgier; George K Lewis
Journal:  Structure       Date:  2020-03-24       Impact factor: 5.006

6.  Consistency of VDJ Rearrangement and Substitution Parameters Enables Accurate B Cell Receptor Sequence Annotation.

Authors:  Duncan K Ralph; Frederick A Matsen
Journal:  PLoS Comput Biol       Date:  2016-01-11       Impact factor: 4.475

7.  Evaluation of Different Parameters of Humoral and Cellular Immune Responses in HIV Serodiscordant Heterosexual Couples: Humoral Response Potentially Implicated in Modulating Transmission Rates.

Authors:  María Julia Ruiz; Jimena Salido; Lorena Abusamra; Yanina Ghiglione; Cintia Cevallos; Gabriel Damilano; Ana María Rodriguez; César Trifone; Natalia Laufer; Luis D Giavedoni; Omar Sued; Horacio Salomón; María Magdalena Gherardi; Gabriela Turk
Journal:  EBioMedicine       Date:  2017-11-03       Impact factor: 8.143

8.  Kappa chain maturation helps drive rapid development of an infant HIV-1 broadly neutralizing antibody lineage.

Authors:  Cassandra A Simonich; Laura Doepker; Duncan Ralph; James A Williams; Amrit Dhar; Zak Yaffe; Lauren Gentles; Christopher T Small; Brian Oliver; Vladimir Vigdorovich; Vidya Mangala Prasad; Ruth Nduati; D Noah Sather; Kelly K Lee; Frederick A Matsen Iv; Julie Overbaugh
Journal:  Nat Commun       Date:  2019-05-16       Impact factor: 14.919

9.  Per-sample immunoglobulin germline inference from B cell receptor deep sequencing data.

Authors:  Duncan K Ralph; Frederick A Matsen
Journal:  PLoS Comput Biol       Date:  2019-07-22       Impact factor: 4.475

Review 10.  Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design.

Authors:  Rino Rappuoli; Matthew J Bottomley; Ugo D'Oro; Oretta Finco; Ennio De Gregorio
Journal:  J Exp Med       Date:  2016-03-28       Impact factor: 14.307

View more
  1 in total

1.  Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage.

Authors:  David Sacks; Kevin Wiehe; Lynn Morris; Penny L Moore
Journal:  J Virol       Date:  2022-05-05       Impact factor: 6.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.